Genmab (NASDAQ:GMAB), a Copenhagen-based biotechnology firm, is preparing to defend itself against a lawsuit filed by AbbVie (NYSE:ABBV) in the U.S. District Court for the Western District of Washington.
The complaint alleges that Genmab, along with ProfoundBio and former AbbVie employees, misappropriated trade secrets tied to the use of disaccharides in drug-linkers for antibody-drug conjugates (ADCs), a cutting-edge class of cancer therapies.
AbbVie’s accusations center on proprietary information purportedly misused by the defendants.
Genmab has firmly denied the claims, calling them baseless and vowing to “vigorously defend” its position in court.
The company underscored its dedication to ethical innovation, positioning itself as “a company deeply rooted in science” focused on advancing antibody therapeutics to enhance patient outcomes.
Despite the legal dispute, Genmab affirmed that its ongoing collaboration with AbbVie on epcoritamab, a promising cancer treatment, will proceed uninterrupted.
The partnership remains a key part of Genmab’s mission to deliver transformative therapies.